Secondary prophylaxis for Clostridioides difficile infection for patients on non- Clostridioides difficile antibiotics: A retrospective cohort study.|https://dx.doi.org/10.1016/j.micinf.2024.105349
Fecal microbiota transplantation: current challenges and future landscapes.|https://dx.doi.org/10.1128/cmr.00060-22
Validation of clinical risk tools for recurrent Clostridioides difficile infection.|https://dx.doi.org/10.1017/ice.2024.75
Clostridioides Difficile: A Concise Review of Best Practices and Updates.|https://dx.doi.org/10.1177/21501319241249645
Fighting against Clostridioides difficile infection: Current medications.|https://dx.doi.org/10.1016/j.ijantimicag.2024.107198
Breaking the Cycle of Recurrent Clostridioides difficile Infections: A Narrative Review Exploring Current and Novel Therapeutic Strategies.|https://dx.doi.org/10.1177/08971900241248883
Rational Design of Live Biotherapeutic Products for the Prevention of Clostridioides difficile Infection.|https://dx.doi.org/10.1101/2024.04.30.591969
Offline Two-Dimensional Liquid Chromatography-Mass Spectrometry for Deep Annotation of the Fecal Metabolome Following Fecal Microbiota Transplantation.|https://dx.doi.org/10.1021/acs.jproteome.4c00022
Clostridioides difficile toxin B subverts germinal center and antibody recall responses by stimulating a drug-treatable CXCR4-dependent mechanism.|https://dx.doi.org/10.1016/j.celrep.2024.114245
Protection against Clostridioides difficile disease by a naturally avirulent C. difficile strain.|https://dx.doi.org/10.1101/2024.05.06.592814
[The new guideline for gastrointestinal infections].|https://dx.doi.org/10.1055/a-2183-6418
"Primum, non nocere": The Epidemiology of Toxigenic Clostridioides difficile Strains in the Antibiotic Era-Insights from a Prospective Study at a Regional Infectious Diseases Hospital in Eastern Europe.|https://dx.doi.org/10.3390/antibiotics13050461
A Comparison of Currently Available and Investigational Fecal Microbiota Transplant Products for Recurrent Clostridioides difficile Infection.|https://dx.doi.org/10.3390/antibiotics13050436
Alternative treatment of recurrent Clostridioides difficile infection in adults by fecal transplantation: an overview of phase I-IV studies from Clinicaltrials.gov.|https://dx.doi.org/10.3389/fmicb.2024.1374774
Exploring the Toxin-Mediated Mechanisms in Clostridioides difficile Infection.|https://dx.doi.org/10.3390/microorganisms12051004
Estimating Clostridioides difficile infection-associated readmission rates: A systematic review and meta-analysis.|https://dx.doi.org/10.1017/ice.2024.94
Microbiota restoration therapies for recurrent Clostridioides difficile infection reach an important new milestone.|https://dx.doi.org/10.1177/17562848241253089
Efficacy of Fecal Microbiota (REBYOTA) in Recurrent Clostridium difficile Infections: A Systematic Review and Meta-Analysis.|https://dx.doi.org/10.7759/cureus.58862
Expression of Concern: Clostridium transplantifaecale sp. nov., a new bacterium isolated from patient with recurrent Clostridium difficile infection.|https://dx.doi.org/10.1016/j.nmni.2024.101280
Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Clostridioides difficile infection - An observational cohort study.|https://dx.doi.org/10.1016/j.heliyon.2024.e30742
Exploring the therapeutic potential of endolysin CD27L_EAD against Clostridioides difficile infection.|https://dx.doi.org/10.1016/j.ijantimicag.2024.107222
Estimating excess mortality and economic burden of Clostridioides difficile infections and recurrences during 2015-2019: the RECUR Germany study.|https://dx.doi.org/10.1186/s12879-024-09422-w
